References
- Piel FB, Steinberg MH, Rees DC, et al. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573. doi: 10.1056/NEJMra1510865
- Henry ER, Metaferia B, Li Q, et al. Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin. Blood. 2021;138(13):1172–1181. doi: 10.1182/blood.2021012070
- Centers for Disease Control and Prevention. Data & statistics on sickle cell disease. 2023 Jul 6 [cited 2023 Oct 23]. Available from: https://www.cdc.gov/ncbddd/sicklecell/data.html
- Brandow AM, Liem RI. Advances in the diagnosis and treatment of sickle cell disease. J Hematol Oncol. 2022 Mar 3;15(1):20. doi: 10.1186/s13045-022-01237-z PMID: 35241123; PMCID: PMC8895633.
- Kavanagh PL, Fasipe TA, Wun T. Sickle cell disease: a review. JAMA. 2022;328(1):57–68. doi: 10.1001/jama.2022.10233
- Pace BS, Starlard-Davenport A, Kutlar A. Sickle cell disease: progress towards combination drug therapy. Br J Haematol. 2021 Jul;194(2):240–251. doi: 10.1111/bjh.17312 Epub 2021 Jan 20. PMID: 33471938; PMCID: PMC8282668.
- Johnson KM, Jiao B, Ramsey SD, et al. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2023;7(3):365–374. doi: 10.1182/bloodadvances.2021006281
- Cronin RM, Hankins JS, Byrd J, et al. Risk factors for hospitalizations and readmissions among individuals with sickle cell disease: results of a U.S. survey study. Hematology. 2019;24(1):189–198. doi: 10.1080/16078454.2018.1549801
- Weaver SB, Rungkitwattanakul D, Singh D. Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in adults with sickle cell disease. J Pharm Pract. 2023;36(1):139–148. doi: 10.1177/08971900211026644
- Dela-Pena JC, King MA, Brown J, et al. Incorporation of novel therapies for the management of sickle cell disease: a pharmacist’s perspective. J Oncol Pharm Pract. 2022;28(3):646–663. doi: 10.1177/10781552211072468
- Food and Drug Administration. Crizanlizumab. 2019 [cited 2023 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761128s000lbl.pdf
- Food and Drug Administration. L-glutamine. 2017 [cited 2023 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208587s000lbl.pdf
- Food and Drug Administration. Hydroxyurea. 1998 [cited 2023 Aug 3]. Available from: https://packageinserts.bms.com/pi/pi_droxia.pdf
- Food and Drug Administration. Voxelotor. 2019 [cited 2023 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213137s000lbl.pdf
- Liem RI, Lanzkron S, Coates TD, et al. American society of hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019;3(23):3867–3897. doi: 10.1182/bloodadvances.2019000916
- Food and Drug Administration. Darbepoetin alfa. 2001 [cited 2023 Aug 3]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103951orig1s5173_103951orig1s5258lbl.pdf
- Ali MA, Ahmad A, Chaudry H, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020;92:11–18.e1. doi: 10.1016/j.exphem.2020.08.008
- Howard J, Hemmaway CJ, Telfer P, et al. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 2019;133(17):1865–1875. doi: 10.1182/blood-2018-08-868893
- Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519. doi: 10.1056/NEJMoa1903212
- Howard J, Ataga KI, Brown RC, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323–e333. doi: 10.1016/S2352-3026(21)00059-4
- Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members [published correction appears in JAMA. 2014 Nov 12;312(18): 1932] [published correction appears in JAMA. 2015 Feb 17;313(7): 729]. JAMA. 2014;312(10):1033–1048. doi: 10.1001/jama.2014.10517
- Han J, Zhou J, Kondragunta V, et al. Erythropoiesis-stimulating agents in sickle cell anaemia. Br J Haematol. 2018;182(4):602–605. doi: 10.1111/bjh.14846
- Bunn HF, Longo DL. Oxygen delivery in the treatment of anemia. N Engl J Med. 2022;387(25):2362–2365. doi: 10.1056/NEJMra2212266
- Little JA, McGowan VR, Kato GJ, et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the national institutes of health and a literature review. Haematologica. 2006;91(8):1076–1083.